FORM 3

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

### OMB Number: INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF Estimated average burden **SECURITIES**

OMB APPROVAL 3235-0104 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Bachleda Mark	2. Date of E Requiring S (Month/Day 10/08/202	tatement /Year)	3. Issuer Name and Ticker or Trading Symbol Galera Therapeutics, Inc. [ GRTX ]					
(Last) (First) (Middle) C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD #100			4. Relationship of Reporting Person(state) Issuer (Check all applicable) Director I 10% of the control of the c		) Owner (specify	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  Provided to the Company of the Compa		
(Street)  MALVERN PA 19355  (City) (State) (Zip)			Chief Commerc	ial Office	PT	X Form filed by One Reporting Person Form filed by More than One Reporting Person		
Table I - Non-Derivative Securities Beneficially Owned								
Ta	ıble I - Non	-Derivativ	e Securities Benefic	cially O	wned			
1. Title of Security (Instr. 4)	ıble I - Non	2	. Amount of Securities Beneficially Owned (Instr.	3. Owner Form: I (D) or II (I) (Inst	ership 4. Direct O	. Nature of Indire wnership (Instr.		
1. Title of Security (Instr. 4)	Table II - D	2 E 4 erivative	. Amount of Securities Beneficially Owned (Instr.	3. Owner Form: I (D) or II (I) (Insti	ership 4. Direct O ndirect r. 5)			
1. Title of Security (Instr. 4)	Table II - D	erivative s, warran	a. Amount of Securities Beneficially Owned (Instr. b) Securities Beneficia	3. Owner Form: I (D) or II (I) (Institute Securities	ership 4. Direct O ndirect r. 5)	5. OWNERSHIP (Instr.		

# Explanation of Responses:

## Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

/s/ J. Mel Sorensen,

Attorney-in-Fact for Mark 10/12/2021

Date

Bachleda

\*\* Signature of Reporting

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB

#### POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Galera Therapeutics, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
- execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of October, 2021.

Signature: /s/ Mark J. Bachleda

Print Name: Mark J. Bachleda

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

J. Mel Sorensen Christopher Degnan